In vivo radioprotective effect of AcSDKP on canine myelopoiesis

[1]  J. Jackson,et al.  In vivo protective effects of tetrapeptide AcSDKP, with or without granulocyte colony-stimulation factor, on murine progenitor cells after sublethal irradiation. , 1996, Experimental hematology.

[2]  K. Matsushima,et al.  Tumor necrosis factor (TNF) is a physiologic regulator of hematopoietic progenitor cells: increase of early hematopoietic progenitor cells in TNF receptor p55-deficient mice in vivo and potent inhibition of progenitor cell proliferation by TNF alpha in vitro. , 1995, Blood.

[3]  H. Deeg,et al.  Inhibition of hematopoiesis in long-term marrow cultures established on adherent layers from AcSDKP-treated dogs. , 1995, Experimental hematology.

[4]  D. Bonnet,et al.  Comparison of the inhibitory effect of AcSDKP, TNF-alpha, TGF-beta, and MIP-1 alpha on marrow-purified CD34+ progenitors. , 1995, Experimental hematology.

[5]  C. Eaves,et al.  The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism. , 1994, Blood.

[6]  J. Neglia,et al.  Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. , 1994, Blood.

[7]  P. Carde.  [Inhibitors of hematopoiesis: from physiology to therapy]. , 1994, Bulletin de l'Academie nationale de medecine.

[8]  D. Bonnet,et al.  Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors. , 1993, Blood.

[9]  M. Tubiana,et al.  Ways of minimising hematopoietic damage induced by radiation and cytostatic drugs--the possible role of inhibitors. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  D. Bonnet,et al.  [Effects of the tetrapeptide AcSDKP on normal and leukemic bone marrow]. , 1993, Nouvelle revue francaise d'hematologie.

[11]  H. Deeg,et al.  Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. , 1993, International journal of radiation oncology, biology, physics.

[12]  H. Deeg,et al.  Effects of recombinant canine stem cell factor, a c-kit ligand, and recombinant granulocyte colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. , 1993, Blood.

[13]  A. Riches,et al.  The mechanism of action of the tetrapeptide Acetyl‐N‐Ser‐Asp‐Lys‐Pro (AcSDKP) in the control of haematopoietic stem cell proliferation , 1992, Cell proliferation.

[14]  S. Aizawa,et al.  Biological activities of tetrapeptide AcSDKP on hemopoietic cell binding to the stromal cell in vitro. , 1992, Experimental hematology.

[15]  M. Moore.  Does stem cell exhaustion result from combining hematopoietic growth factors with chemotherapy? If so, how do we prevent it? , 1992, Blood.

[16]  C. Bloomfield,et al.  Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. , 1992, Seminars in oncology.

[17]  R. Césaire,et al.  The tetrapeptide AcSDKP, an inhibitor of the cell-cycle status for normal human hematopoietic progenitors, has no effect on leukemic cells. , 1992, Experimental hematology.

[18]  A. Bogdén,et al.  Amelioration of Chemotherapy‐Induced Toxicity by Cotreatment with AcSDKP, a Tetrapeptide Inhibitor of Hematopoietic Stem Cell Proliferation , 1991, Annals of the New York Academy of Sciences.

[19]  J. Mary,et al.  Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP. , 1990, Experimental hematology.

[20]  E. Lauret,et al.  Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP. II. Unresponsiveness of isolated adult rat hepatocytes, 3T3, FDC-P2, and K562 cell lines to AcSDKP. Possible involvement of intermediary cell(s) in the mechanism of AcSDKP action. , 1989, Experimental hematology.

[21]  R Storb,et al.  Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. , 1989, Blood.

[22]  R. Storb,et al.  Allogeneic Bone‐Marrow Transplantation , 1983, Immunological reviews.

[23]  H. Deeg,et al.  High-dose total-body irradiation and autologous marrow reconstitution in dogs: dose-rate-related acute toxicity and fractionation-dependent long-term survival. , 1981, Radiation research.

[24]  E. Frindel,et al.  Inhibition of CFU-S entry into cell cycle after irradiation and drug treatment. , 1978, Biomedicine / [publiee pour l'A.A.I.C.I.G.].

[25]  E. Frindel,et al.  Inhibition of CFU entry into cycle by a bone marrow extract. , 1977, Experimental hematology.

[26]  H. Withers,et al.  Four R's of radiotherapy , 1975 .